DeutschNewstral
Article
jdsupra.com on 2022-08-08 17:29
Celltrion Files IND with FDA for Adalimumab Biosimilar
Related news
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com
- FDA Approves Pfizer’s Adalimumab Biosimilar ABRILADAjdsupra.com
- Teva and Alvotech’s Adalimumab Biosimilar Receives Interchangeable Status at FDAjdsupra.com
- FDA Approves Boehringer Ingelheim’s Adalimumab Biosimilarjdsupra.com
- FDA Approves Coherus’ Adalimumab Biosimilar YUSIMRY™jdsupra.com
- Hikma and Celltrion Announce Collaboration to Market Adalimumab Biosimilar YUFLYMA in Middle East and North Africajdsupra.com
- FDA accepts Celltrion/Teva BLA for biosimilar of Rituxan®jdsupra.com
- FDA Approves 25th Biosimilarjdsupra.com
- Recent Adalimumab Biosimilar Updatesjdsupra.com
- Recent Adalimumab Biosimilar Developmentsjdsupra.com
- Biosimilar Market Updates: Samsung Biologics, Celltrion, and Alvotechjdsupra.com
- Litigation and Regulatory Update for Alvotech’s Adalimumab Biosimilarjdsupra.com
- Celltrion Completes Application for FDA Approval of CT-P41, Biosimilar of Prolia® / Xgeva®jdsupra.com
- FDA Approves Sandoz’s Biosimilar Pegfilgrastimjdsupra.com
- FDA Approves First Rituximab Biosimilarjdsupra.com
- FDA Approves Celltrion’s Trastuzumab Biosimilarjdsupra.com
- EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com
- China NMPA Approves Adalimumab Biosimilarjdsupra.com
- FDA Implements Biosimilar Action Plan to Boost Biosimilar Competitionjdsupra.com
- Amgen’s Humira Biosimilar Becomes the Fourth FDA Approved Biosimilarjdsupra.com